Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

Introduction Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the effectiveness and safety of rituximab in MS. Patients and methods Observational study of effectiveness (clinical a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2018-07, Vol.265 (7), p.1690-1697
Main Authors: Alcalá, Carmen, Gascón, F., Pérez-Miralles, F., Gil-Perotín, S., Navarré, A., Boscá, I., Coret, F., Casanova, B.
Format: Article
Language:English
Subjects:
Gadolinium
Immunotherapy
Medicine
Medicine & Public Health
Monoclonal antibodies
Multiple sclerosis
Neurology
Neuroradiology
Neurosciences
Original Communication
Patients
Rituximab
Safety
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the effectiveness and safety of rituximab in MS. Patients and methods Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. Results A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% ( p  
ISSN:0340-5354
1432-1459
DOI:10.1007/s00415-018-8899-3